T cells engineered with chimeric antigen receptors, or CAR-T cells, are a very active area of research to treat leukemias and other diseases. Join us for a free webinar to learn the latest. Registration required.
CIRM is now accepting submissions for the first round of funding under CIRM 2.0. The first three programs under the initiative apply to projects that are ready to start or have started a clinical trial.